KYMR Kymera Therapeutics, Inc.
Nasdaq · SEC CIK 1815442 · EDGAR
- Bought, last 12 months
- $172.50M 1 purchases by 1 insiders
- Sold, last 12 months
- $475.84M 50 sales by 11 insiders
- Filings on record
- 212 since 2021-07-06, latest 2026-09-04 18:00
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Booth Bruce | Dir | — | $226.03M |
| BVF PARTNERS L P/IL | Dir, See Remarks, Footnotes | — | $173.67M |
| BAKER FELIX | Dir, 10% | $172.50M | — |
| Mainolfi Nello | CEO, Dir | — | $33.41M |
| Chadwick Jeremy G | COO | — | $15.60M |
| Jacobs Bruce N. | CFO | — | $9.96M |
| Gollob Jared | Chief Medical Off | — | $9.13M |
| Esposito Pamela | Dir | — | $3.05M |
| Goodman Noah | Chief Business Off | — | $2.22M |
| Ridloff Elena | Dir | — | $1.29M |
Transactions 233
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-06-11 | 2025-06-11 | KYMR | Ridloff Elena | Dir | M - OptEx | $20.29 | +4,500 | 4,500 | New | +$91.3K |
| DMT | 2025-06-03 | 2025-06-03 | KYMR | Ridloff Elena | Dir | S - Sale+OE | $46.10 | -12.0K | 4,800 | -71% | -$553.2K |
| DT | 2025-06-03 | 2025-06-03 | KYMR | Ridloff Elena | Dir | M - OptEx | $27.67 | +12.0K | 12.0K | New | +$332.0K |
| DT | 2025-06-03 | 2025-06-03 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +30.0K | 690.5K | +5% | +$62.4K |
| DT | 2025-06-03 | 2025-06-03 | KYMR | Mainolfi Nello | CEO, Dir | S - Sale+OE | $49.00 | -30.0K | 660.5K | -4% | -$1.47M |
| DT | 2025-06-03 | 2025-06-03 | KYMR | Albers Jeffrey W. | Dir | S - Sale+OE | $49.00 | -6,349 | 0 | -100% | -$311.1K |
| DT | 2025-06-03 | 2025-06-03 | KYMR | Albers Jeffrey W. | Dir | M - OptEx | $10.34 | +6,349 | 6,349 | New | +$65.6K |
| DT | 2025-06-03 | 2025-06-03 | KYMR | Esposito Pamela | Dir | S - Sale+OE | $49.04 | -5,000 | 0 | -100% | -$245.2K |
| DT | 2025-06-03 | 2025-06-03 | KYMR | Esposito Pamela | Dir | M - OptEx | $29.55 | +5,000 | 5,000 | New | +$147.8K |
| 2025-05-23 | 2025-05-23 | KYMR | Chadwick Jeremy G | COO | S - Sale | $29.30 | -2,575 | 66.4K | -4% | -$75.4K | |
| D | 2025-04-09 | 2025-04-08 | KYMR | Goodman Noah | Chief Business Off | A - Grant | $0.00 | +50.0K | 50.1K | +61,395% | $0 |
| D | 2025-04-01 | 2025-03-31 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +25.0K | 226.9K | +12% | +$52.0K |
| DM | 2025-03-03 | 2025-03-03 | KYMR | Gollob Jared | Chief Medical Off | S - Sale | $30.45 | -5,740 | 121.0K | -5% | -$174.8K |
| D | 2025-03-03 | 2025-03-03 | KYMR | Gollob Jared | Chief Medical Off | A - Grant | $0.00 | +30.0K | 125.7K | +31% | $0 |
| D | 2025-03-03 | 2025-03-03 | KYMR | Jacobs Bruce N. | CFO | A - Grant | $0.00 | +30.0K | 208.9K | +17% | $0 |
| DM | 2025-03-03 | 2025-03-03 | KYMR | Jacobs Bruce N. | CFO | S - Sale | $30.45 | -7,035 | 201.9K | -3% | -$214.2K |
| DM | 2025-03-03 | 2025-03-03 | KYMR | Chiniara Ellen | CLO | S - Sale | $30.45 | -2,241 | 80.5K | -3% | -$68.2K |
| D | 2025-03-03 | 2025-03-03 | KYMR | Chiniara Ellen | CLO | A - Grant | $0.00 | +27.5K | 82.3K | +50% | $0 |
| DM | 2025-03-03 | 2025-03-03 | KYMR | Chadwick Jeremy G | COO | S - Sale | $30.45 | -1,383 | 67.8K | -2% | -$42.1K |
| D | 2025-03-03 | 2025-03-03 | KYMR | Chadwick Jeremy G | COO | A - Grant | $0.00 | +25.0K | 69.2K | +57% | $0 |
| D | 2025-01-13 | 2025-01-10 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +10.0K | 660.0K | +2% | +$20.8K |
| D | 2025-01-13 | 2025-01-10 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 178.9K | +6% | +$20.8K |
| 2025-01-06 | 2025-01-06 | KYMR | Chiniara Ellen | CLO | S - Sale | $41.75 | -3,129 | 54.8K | -5% | -$130.6K | |
| DT | 2024-12-02 | 2024-12-02 | KYMR | Esposito Pamela | Dir | M - OptEx | $29.55 | +2,500 | 2,500 | New | +$73.9K |
| DT | 2024-12-02 | 2024-12-02 | KYMR | Esposito Pamela | Dir | S - Sale+OE | $49.00 | -2,500 | 0 | -100% | -$122.5K |
| DMT | 2024-09-17 | 2024-09-17 | KYMR | Esposito Pamela | Dir | M - OptEx | $23.86 | +13.5K | 13.5K | New | +$322.1K |
| DMT | 2024-09-17 | 2024-09-17 | KYMR | Esposito Pamela | Dir | S - Sale+OE | $48.28 | -13.5K | 0 | -100% | -$651.8K |
| DT | 2024-08-26 | 2024-08-26 | KYMR | Albers Jeffrey W. | Dir | S - Sale+OE | $49.10 | -5,000 | 0 | -100% | -$245.5K |
| DT | 2024-08-26 | 2024-08-26 | KYMR | Albers Jeffrey W. | Dir | M - OptEx | $10.34 | +5,000 | 5,000 | New | +$51.7K |
| DI | 2024-08-22 | 2024-08-20 | KYMR | 667, L.P. | Dir | P - Purchase | $46.41 | +1 | 5.52M | +0.0% | +$46.41 |
| DMT | 2024-07-16 | 2024-07-15+ | KYMR | Gollob Jared | Chief Medical Off | S - Sale+OE | $45.53 | -39.6K | 95.7K | -29% | -$1.80M |
| DMT | 2024-07-16 | 2024-07-15+ | KYMR | Gollob Jared | Chief Medical Off | M - OptEx | $2.08 | +39.6K | 112.2K | +55% | +$82.4K |
| MI | 2024-07-09 | 2024-07-09 | KYMR | Booth Bruce | Dir | S - Sale | $38.21 | -454.0K | 4.52M | -9% | -$17.35M |
| D | 2024-07-01 | 2024-07-01 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $5.33 | +18.8K | 650.0K | +3% | +$100.1K |
| D | 2024-06-28 | 2024-06-27 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +25.0K | 168.6K | +17% | +$52.0K |
| D | 2024-06-20 | 2024-06-18 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +14.4K | 631.2K | +2% | +$30.0K |
| MI | 2024-06-14 | 2024-06-12+ | KYMR | Booth Bruce | Dir | S - Sale | $35.27 | -26.9K | 4.56M | -0.6% | -$950.2K |
| DMT | 2024-06-07 | 2024-06-07 | KYMR | Horobin Joanna | Dir | S - Sale+OE | $32.99 | -8,500 | 0 | -100% | -$280.4K |
| DT | 2024-06-07 | 2024-06-07 | KYMR | Horobin Joanna | Dir | M - OptEx | $2.08 | +8,500 | 8,500 | New | +$17.7K |
| 2024-05-23 | 2024-05-23 | KYMR | Chadwick Jeremy G | COO | S - Sale | $34.99 | -2,575 | 44.2K | -6% | -$90.1K | |
| MI | 2024-03-15 | 2024-03-14+ | KYMR | Booth Bruce | Dir | S - Sale | $40.25 | -127.5K | 819.2K | -13% | -$5.13M |
| MI | 2024-03-13 | 2024-03-11+ | KYMR | Booth Bruce | Dir | S - Sale | $42.20 | -353.4K | 4.93M | -7% | -$14.91M |
| M | 2024-03-13 | 2024-03-11+ | KYMR | Atlas Venture Associates Opportunity I, LLC | 10% | S - Sale | $42.20 | -292.0K | 4.93M | -6% | -$12.32M |
| MI | 2024-03-13 | 2024-03-11+ | KYMR | Atlas Venture Associates Opportunity I, LLC | 10% | S - Sale | $42.20 | -61.3K | 882.3K | -6% | -$2.59M |
| D | 2024-03-04 | 2024-03-01 | KYMR | Gollob Jared | Chief Medical Off | A - Grant | $0.00 | +24.4K | 99.1K | +33% | $0 |
| DM | 2024-03-04 | 2024-03-04 | KYMR | Gollob Jared | Chief Medical Off | S - Sale | $41.85 | -3,344 | 95.7K | -3% | -$140.0K |
| D | 2024-03-04 | 2024-03-01 | KYMR | Chadwick Jeremy G | COO | A - Grant | $0.00 | +13.4K | 46.8K | +40% | $0 |
| DM | 2024-03-04 | 2024-03-04 | KYMR | Jacobs Bruce N. | CFO | S - Sale | $41.85 | -3,934 | 143.9K | -3% | -$164.7K |
| D | 2024-03-04 | 2024-03-01 | KYMR | Jacobs Bruce N. | CFO | A - Grant | $0.00 | +31.2K | 146.3K | +27% | $0 |
| D | 2024-03-04 | 2024-03-01 | KYMR | Chiniara Ellen | CLO | A - Grant | $0.00 | +21.8K | 56.0K | +64% | $0 |
| DT | 2024-02-29 | 2024-02-27 | KYMR | Gollob Jared | Chief Medical Off | M - OptEx | $2.08 | +400 | 75.1K | +0.5% | +$832 |
| DT | 2024-02-29 | 2024-02-27 | KYMR | Gollob Jared | Chief Medical Off | S - Sale+OE | $45.00 | -400 | 74.7K | -0.5% | -$18.0K |
| DMT | 2024-02-21 | 2024-02-20+ | KYMR | Albers Jeffrey W. | Dir | M - OptEx | $10.34 | +5,000 | 615 | New | +$51.7K |
| DMT | 2024-02-21 | 2024-02-20+ | KYMR | Albers Jeffrey W. | Dir | S - Sale+OE | $39.05 | -5,000 | 0 | -100% | -$195.3K |
| DT | 2024-02-09 | 2024-02-09 | KYMR | Gollob Jared | Chief Medical Off | M - OptEx | $2.08 | +46.1K | 120.8K | +62% | +$96.0K |
| DMT | 2024-02-09 | 2024-02-09 | KYMR | Gollob Jared | Chief Medical Off | S - Sale+OE | $35.50 | -46.1K | 74.7K | -38% | -$1.64M |
| DT | 2024-01-23 | 2024-01-23 | KYMR | Albers Jeffrey W. | Dir | S - Sale+OE | $30.05 | -10.0K | 0 | -100% | -$300.5K |
| DT | 2024-01-23 | 2024-01-23 | KYMR | Albers Jeffrey W. | Dir | M - OptEx | $10.34 | +10.0K | 10.0K | New | +$103.4K |
| 2024-01-05 | 2024-01-04 | KYMR | Chiniara Ellen | CLO | S - Sale | $22.58 | -3,295 | 34.2K | -9% | -$74.4K | |
| D | 2024-01-02 | 2024-01-02 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +9,000 | 615.6K | +1% | +$18.7K |
| DM | 2023-11-06 | 2023-11-03 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +20.0K | 606.6K | +3% | +$41.6K |
| M | 2023-11-06 | 2023-11-02+ | KYMR | BVF II GP LLC | Dir, See Remarks, Footnotes | P - Purchase | $12.80 | +414.1K | 284.5K | New | +$5.30M |
| D | 2023-08-08 | 2023-08-08 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +12.0K | 586.6K | +2% | +$25.0K |
| D | 2023-06-02 | 2023-06-02 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 115.0K | +10% | +$20.8K |
| D | 2023-05-22 | 2023-05-22 | KYMR | Chadwick Jeremy G | COO | A - Grant | $0.00 | +33.3K | 33.3K | New | $0 |
| DM | 2023-03-03 | 2023-03-02 | KYMR | Gollob Jared | Chief Medical Off | S - Sale | $31.00 | -1,298 | 74.7K | -2% | -$40.2K |
| D | 2023-03-03 | 2023-03-01 | KYMR | Gollob Jared | Chief Medical Off | A - Grant | $0.00 | +18.8K | 76.0K | +33% | $0 |
| DM | 2023-03-03 | 2023-03-02 | KYMR | Caughey Elaine | Chief Business Off | S - Sale | $31.00 | -714 | 19.1K | -4% | -$22.1K |
| D | 2023-03-03 | 2023-03-01 | KYMR | Caughey Elaine | Chief Business Off | A - Grant | $0.00 | +10.6K | 19.7K | +115% | $0 |
| D | 2023-03-03 | 2023-03-01 | KYMR | Jacobs Bruce N. | CFO | A - Grant | $0.00 | +23.8K | 105.9K | +29% | $0 |
| DM | 2023-03-03 | 2023-03-02 | KYMR | Jacobs Bruce N. | CFO | S - Sale | $31.00 | -1,370 | 104.6K | -1% | -$42.5K |
| M | 2023-01-13 | 2023-01-11+ | KYMR | Atlas Venture Opportunity Fund I, L.P. | 10% | S - Sale | $30.22 | -98.8K | 5.05M | -2% | -$2.99M |
| MI | 2023-01-13 | 2023-01-11+ | KYMR | Atlas Venture Opportunity Fund I, L.P. | 10% | S - Sale | $30.22 | -27.7K | 890.1K | -3% | -$835.9K |
| M | 2023-01-13 | 2023-01-11+ | KYMR | BIOTECHNOLOGY VALUE FUND II LP | Dir, See Remarks, Footnotes | P - Purchase | $30.51 | +41.0K | 2.49M | +2% | +$1.25M |
| MI | 2023-01-13 | 2023-01-11+ | KYMR | Booth Bruce | Dir | S - Sale | $30.22 | -126.5K | 4.97M | -2% | -$3.82M |
| D | 2023-01-04 | 2023-01-03 | KYMR | Chiniara Ellen | CLO | A - Grant | $0.00 | +37.5K | 37.5K | New | $0 |
| M | 2022-12-16 | 2022-12-14+ | KYMR | Atlas Venture Associates Opportunity I, LLC | 10% | S - Sale | $31.36 | -298.6K | 5.25M | -5% | -$9.36M |
| MI | 2022-12-16 | 2022-12-14+ | KYMR | Atlas Venture Associates Opportunity I, LLC | 10% | S - Sale | $31.36 | -83.6K | 917.8K | -8% | -$2.62M |
| MI | 2022-12-16 | 2022-12-14+ | KYMR | Booth Bruce | Dir | S - Sale | $31.36 | -382.2K | 926.2K | -29% | -$11.99M |
| D | 2022-12-08 | 2022-12-08 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +10.0K | 573.7K | +2% | +$20.8K |
| MI | 2022-11-04 | 2022-11-02+ | KYMR | Booth Bruce | Dir | S - Sale | $30.01 | -220.0K | 1.00M | -18% | -$6.60M |
| MI | 2022-11-04 | 2022-11-02+ | KYMR | Atlas Venture Associates Opportunity I, L.P. | 10% | S - Sale | $30.01 | -48.1K | 1.00M | -5% | -$1.44M |
| M | 2022-11-04 | 2022-11-02+ | KYMR | Atlas Venture Associates Opportunity I, L.P. | 10% | S - Sale | $30.01 | -171.9K | 5.44M | -3% | -$5.16M |
| MI | 2022-11-01 | 2022-10-28+ | KYMR | Atlas Venture Fund X, L.P. | 10% | S - Sale | $30.26 | -63.1K | 1.05M | -6% | -$1.91M |
| M | 2022-11-01 | 2022-10-28+ | KYMR | Atlas Venture Fund X, L.P. | 10% | S - Sale | $30.26 | -225.6K | 5.69M | -4% | -$6.82M |
| MI | 2022-11-01 | 2022-10-28+ | KYMR | Booth Bruce | Dir | S - Sale | $30.26 | -288.7K | 5.54M | -5% | -$8.74M |
| D | 2022-10-24 | 2022-10-21 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 81.3K | +14% | +$20.8K |
| D | 2022-10-17 | 2022-10-17 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 71.3K | +16% | +$20.8K |
| DM | 2022-10-17 | 2022-10-17 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +59.7K | 561.9K | +12% | +$124.2K |
| M | 2022-08-23 | 2022-08-22 | KYMR | BIOTECHNOLOGY VALUE FUND II LP | Dir, See Remarks, Footnotes | P - Purchase | $26.00 | +545.5K | 1.86M | +41% | +$14.18M |
| M | 2022-05-31 | 2022-05-26+ | KYMR | BVF PARTNERS L P/IL | Dir, See Remarks, Footnotes | P - Purchase | $14.34 | +289.4K | 1.60M | +22% | +$4.15M |
| M | 2022-05-24 | 2022-05-20 | KYMR | BIOTECHNOLOGY VALUE FUND L P | Dir, See Remarks, Footnotes | P - Purchase | $14.00 | +10.1K | 2.04M | +0.5% | +$141.4K |
| M | 2022-05-09 | 2022-05-05+ | KYMR | BVF INC/IL | Dir, See Remarks, Footnotes | P - Purchase | $19.46 | +250.0K | 2.03M | +14% | +$4.87M |
| DM | 2022-05-04 | 2022-05-04 | KYMR | Gollob Jared | Chief Medical Off | M - OptEx | $1.69 | +20.0K | 57.3K | +54% | +$33.7K |
| D | 2022-05-03 | 2022-05-03 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +20.0K | 502.2K | +4% | +$41.6K |
| D | 2022-05-03 | 2022-05-03 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +20.0K | 60.8K | +49% | +$41.6K |
| D | 2022-03-03 | 2022-03-01 | KYMR | Caughey Elaine | Chief Business Off | A - Grant | $0.00 | +7,000 | 7,000 | New | $0 |
| D | 2022-03-03 | 2022-03-01 | KYMR | Gollob Jared | Chief Medical Off | A - Grant | $0.00 | +12.6K | 37.3K | +51% | $0 |
| D | 2022-03-03 | 2022-03-01 | KYMR | Jacobs Bruce N. | CFO | A - Grant | $0.00 | +13.3K | 40.8K | +48% | $0 |
| M | 2022-01-31 | 2022-01-27+ | KYMR | BVF INC/IL | See Explanation of Responses | P - Purchase | $38.96 | +130.3K | 1.88M | +7% | +$5.08M |
Purchase Sale Sale after option exercise All abbreviations